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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A37Results: Of the 351 subjects enrolled in the MeTeOR Trial, 292 had
complete data on outcomes and covariates used in this analysis. 57%
were female and mean age was 58 (SD 7). 141 of these subjects were
randomized to APM and received surgery. Another 93 subjects were
randomized to PT and continued to receive PT, while 58 were
randomized to PT and crossed over to receive APM. Forty percent of
cross-overs occurred within three months of randomization. In multi-
variable analyses, factors associated with a higher likelihood of crossing
over to have APM among those randomized to PT included baseline
WOMAC Pain score > 40 (RR 1.13, 95% CI: 1.05, 1.20), duration of
symptoms less than one year (RR 1.08, 95% CI: 1.01, 1.15) and ability to
extend the knee fully (RR 1.07, 95 % CI: 0.99, 1.16). The model had a c-
statistic of 0.70. The proportion of subjects who achieved a 10 point
improvement in pain score after six months of follow-up ranged from
80% in those randomized to APM, 73% in those randomized to PT who
did not cross over and 69% in subjects who crossed over to APM. In
multivariate analyses, those who crossed over to APM were 23% less
likely to achieve a 10-point improvement in pain score than subjects
originally randomized to APM (RR 0.77 95% CI: 0.54, 0.92), adjusting for
baseline pain and duration of symptoms.
Conclusions: These data suggest that patients assigned to PT who were
most likely to cross over to APM included those with a more acute and
painful onset - characterized by short duration of symptoms, high level
of pain and least extension loss. The ﬁndings also suggest that patients
who cross over to surgery are 23% less likely to experience improve-
ment in pain than those originally randomized to APM. This difference
should be interpreted with care as the groups are not randomized.
Taken together, these ﬁndings suggest a need for 1) further research to
identify patients for whom initial PT is less likely to be successful and 2)
strategies to support patients who do not improve with PT, as the
results of APM in these patients may be worse than in those treated
with APM at the outset.
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THE ROLE OF ERYTHROMYCIN/GHRELIN AXIS IN ARTICULAR
CARTILAGE MAINTENANCE
L. Zeng y, T. Uchimura y, A.T. Foote y, T. Shi z, W. Ren z. y Tufts Univ. Sch. of
Med., Boston, MA, United States; zWayne State Univ., Detroit, MI, United
States
Purpose: The goal of this research was to investigate the effects of a
well-known antibiotic, erythromycin, and a well-known “hunger hor-
mone”, ghrelin, on chondrocytes. In recent years, certain macrolide
antibiotics were found to combat inﬂammation in the lung and the
bone, even though they did not affect bacterial growth at the concen-
trations used, suggesting that this activity is independent of its anti-
biotic properties. Among the macrolide antibiotics, only EM has been
tested in one human OA clinical trial, which showed reduction of joint
effusion and pain over the course of 4 months, but how EM achieved
such an effect was not assessed in this study.
Ghrelin is a 28 amino acid long peptide best known as the “hunger
hormone”, since its level is highest before meals and drops after meals.
Ghrelin is reported to have protective effects against pulmonary and
brain injuries in combating inﬂammation and pain. As labeled EM has
been reported to bind to puriﬁed ghrelin receptor, we investigated
whether EM acts through ghrelin receptor on chondrocytes, and
whether ghrelin has a similar activity on chondrocyte gene expression.
Methods: In vitro: Normal human articular chondrocytes (Lonza) or
mouse immature articular chondrocytes were cultured in the presence
or absence of IL-1b, erythromycin and ghrelin (varying amounts) for 4
days followed by RT-PCR. For Western blot analysis of NFkB signaling,
samples were harvested 1hr after IL-1b treatment. In vivo: CD1 mice
were injected either with monosodium iodoacetate (MIA, 62.5mg)
intrarticularly or erythromycin (400 mg) or both, with PBS controls (6/
group). Immunohistochemistry (IHC) was performed 10 days later, and
cartilage damage was quantiﬁed by the OARSI scoring system. Ex vivo:
human OA cartilage slices were cultured in the presence of ghrelin or
PBS for 3 weeks and matrix level was analyzed by IHC and safranin/O
staining. Data are reported as mean ± standard deviation. For para-
metric data, statistical analysis was performed using a one-way analysis
of variance followed by post-hoc Tukey test. For nonparametric data
(OARSI scores), statistical analysis was performed using the Kruskal-
Wallis test followed by Mann-Whitney U test with Bonferroni correc-
tion. P-values of <0.05 were considered signiﬁcant.Results: 1. Erythromycin inhibited IL-1b induced collagen II reduction
and iNOS, MMP1, 3, 9, 13 induction in human chondroctyes (data not
shown), and inhibited IL-1b-induced NFkB nuclear localization (Fig. 1A).
To evaluate the effect of erythromycin on cartilage damage in vivo, we
injected MIA into the knee joint. This model is an OA and pain model
because it demonstrates all features of injury-induced OA, even though
MIA is not present naturally. We found that erythromycin does not
affect cartilage matrix production in normal conditions, but sig-
niﬁcantly reduced MIA-induced matrix loss, even though different
medial-lateral zones have different extent of damage (Fig. 1B and 1C).
2. By utilizing an anti-erythromycin antibody, we found dosage-
dependent binding of erythromycin to mouse articular chondrocytes
after just 3hr or 1 day of erythromycin addition (Fig. 1D). Consistent
with a prior report of erythromycin binding to the ghrelin receptor
GHS-R1, increasing levels of ghrelin administration displaced eryth-
romycin binding to the chondrocytes (data not shown). Furthermore,
such binding was diminished in chondrocytes from the GHS-R KO mice
(Fig. 1E). Correspondingly, erythromycin did not inhibit MMP13
expression in GHS-R KO chondrocytes (Fig. 1F).
3. Ghrelin administration inhibited IL-1b-induced iNOS and MMP
expression in human chondrocytes (data not shown), and this activity
was lost in chondrocytes from GHS-R KO mice (Fig. 1G). Furthermore,
ghrelin inhibited IL-1b-induced NFkB nuclear localization in chon-
drocytes, and increased cartilage matrix levels in human OA cartilage
explant cultures (data not shown).
Conclusions: This work provides a novel link of two molecules that are
not known to regulate chondrocyte gene expression. We show that
erythromycin and ghrelin act through the ghrelin receptor to inhibit
catabolic activities in articular chondrocytes, which may represent a
new mechanism in the control of matrix loss in arthritis.
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DIO2-DEFICIENT MICE ARE PROTECTED AGAINST CARTILAGE
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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A38Purpose: Previously, we identiﬁed the DIO2 gene as human OA sus-
ceptibility gene and showed detrimental DIO2 up-regulation in OA
affected cartilage. Additionally, we showed that pharmacological
inhibition of DIO2 signaling in a human 3D chondrogenesis cell-model
confers prolonged cartilage matrix homeostasis. Here we aim to inves-
tigate the beneﬁcial effect of deﬁcient deiodinase iodothyronine type-2
(DIO2) in OA by studying the effects of forced mechanical loading on in
vivo joint cartilage tissue homeostasis in Dio2 knockout mice.
Methods: Wild-type and C57BL/6-Dio2 -/- -mice were subjected to a
stringent, forced running regime for one hour per day for three weeks.
Severity of osteoarthritiswas assessed by histological scoring for cartilage
damage and synovitis. Genomewide gene expressionwas determined in
knee-cartilage bymicroarray analysis (IlluminaMouseWG-6 v2). STRING-
db analyses were applied to determine enrichment for speciﬁc pathways
and to visualize protein-protein interaction (PPI)-networks.
Results:Dio2-deﬁcientmice showed signiﬁcant less cartilage damage (P
< 0.0001) and reduced severity of synovitis (P ¼ 0.0184) after admin-
istration to a treadmill running model of OA. In the wild-type-speciﬁc
and the overall analyses we observed in total, 158 probes representing
147 unique genes signiﬁcantly differential expressed with a fold-change
 1.5 upon forced exercise. Among these are genes known for their
associationwith OA (e.g. Mef2c, Egfr, Ctgf, Prg4 and Ctnnb1), supporting
the use of forced running as an OA-model in mice. However, in the
knockout-speciﬁc analysis, we observed no signiﬁcant differential
expression in articular cartilage upon the running regime, suggesting an
attenuated response to biomechanical burden. Among the differential
expressed genes, thyroid signaling was found to interact directly with
the differential expressed genes through, Ctgf and Egfr, via thyroid
receptor alpha (Thra) and retinoid x receptor (Rxra). Dio2-deﬁcientmice
showed signiﬁcantly less cartilage damage and signs of synovitis.
Conclusions:We ﬁnd that Dio2 deﬁciency has a protective effect on the
homeostasis of articular cartilage in the knee-joints of mice undergoing
a forced running regime. This is consistent with our earlier ﬁndings,
showing that pharmacological inhibition of deiodinases in a human in
vitro chondrogenesis model has a beneﬁcial effect on the early for-
mation and maintenance of articular cartilage ECM. It is therefore
hypothesized that control of thyroid hormone signaling, both during
development and adult cartilage maintenance, is essential to ensure
normal bone and cartilage homeostasis, and that it could act as the
master-switch that forces maturational arrested chondrocytes to re-
activate the endochondral ossiﬁcation process, leading to articular
cartilage destruction. Our results show that interfering with intra-
cellular thyroid hormone levels could be a powerful way to oppose the
pathological events that are occurring in OA.
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SYNOVIAL MACROPHAGES PROMOTE TGF-b SIGNALING AFTER
INTRA-ARTICULAR INJECTIONS OF OXIDIZED LDL IN NAÏVE
MURINE KNEE JOINTS, PREVENTING PRODUCTION OF PRO-
INFLAMMATORY FACTORS S100A8/9, CHEMOKINES AND
AGGRECANASE-INDUCED NEO-EPITOPES
W. de Munter y, A.B. Blom y, P.M. van der Kraan y, J. Roth z, T. Vogl z,
W.B. van den Berg y, P.L. van Lent y. yRadboud Univ. Med. Ctr., Nijmegen,
Netherlands; z Inst. of Immunology, Muenster, Germany
Purpose: In previous studies we found that synovial macrophages
regulate joint pathology during experimental osteoarthritis (OA) and,
more recently, we found that high systemic levels of LDL aggravate joint
pathology during experimental OA with synovitis. LDL in inﬂamed
synovium is oxidized and taken-up by macrophages via scavenger
receptor A and CD36, leading to an activated macrophage phenotype. In
this study, we investigate whether direct injection of oxLDL into a
normal murine knee joint induces joint pathology and elucidate the role
of synovial macrophages in that process.
Methods: Knee joints of C57BL/6 mice were injected at ﬁve consecutive
days with 6 mL (1.2 mg/mL) oxLDL, LDL, or an equal volume of vehicle
(PBS). This same procedure was done in mice which were depleted of
synovialmacrophagesby intra-articular injectionof clodronate liposomes
seven days prior to the (ox)LDL or vehicle injections. Joint pathology was
investigated by immunohistochemistry and RNA expression and protein
production by synovium were determined using RT-PCR and luminex,
respectively. Active TGF-b was measured using a functional CAGA-luci-
ferase assay. Data are depicted as mean ± standard deviation.
Results: LDL and oxLDL injection in naïve knee joints did not increase
synovial thickening, or production of pro-inﬂammatory factors (IL-1b,IL-6 and S100A8/9) compared to vehicle injection. Levels of active TGF-b
in synovial wash-outs was, however, signiﬁcantly increased by 33%
(from 84.7 ng/mL/g synovium ± 14.4 to 113.0 ng/mL/g synovium ± 33.3;
p<0.05). Immunohistochemistry of total knee joints showed that oxLDL
injection decreased formation of aggrecanase-induced neo-epitopes
(NITEGE) compared with vehicle injections (3.6 times; p<0.05), espe-
cially in areas along the bone margins that are prone to develop
osteophytes (from arbitrary score 1.19 ± 0.57 to 0.33 ± 0.30; p<0.05).
In contrast, repeated injections of oxLDL in macrophage-depleted knee
joints led to a 3.1 fold increase of synovial thickening (due to cell inﬂux),
compared with injection of vehicle (p<0.01), while LDL injections did
not alter synovial thickening. Protein levels of S100A8/A9, markers for
inﬂammation, were signiﬁcantly increased in synovial wash-outs of
oxLDL injected joints, compared with LDL (fold increase 5.6; p<0.05) or
vehicle (fold increase 8.3; p<0.01) injection. RNA levels of chemokines
CCL2 (Mcp-1) and CCL3 (Mip-1a) were also signiﬁcantly upregulated
after oxLDL injections (6.7 fold and 4.6 fold, respectively; p<0.01). No
raise in active TGF-b was measured in macrophage-depleted joints.
NITEGE expression was markedly increased (fold increase 1.92) in the
synovial-cartilage contact areas after oxLDL injection (p<0.05).
Conclusions: Synovial macrophages promote anabolic effects after
oxLDL injections in knee joints, supporting earlier studies which show
increased ectopic bone formation during LDL-rich conditions in exper-
imental osteoarthritis. In absence of synovial macrophages, however,
oxLDL induces cell inﬂux, production of pro-inﬂammatorymediators and
aggrecanase activity, thereby increasing catabolic activity.
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CONDITIONAL DELETION OF CTGF REVEALS A PIVOTAL ROLE FOR
CTGF ON ACTIVATING THE LATENT COMPLEX OF TGFb
X. Tang, T. Vincent. Univ. of Oxford, Oxford, United Kingdom
Purpose: Work from our lab has identiﬁed an important role for the
pericellular matrix (PCM) of cartilage sequestering regulatory mole-
cules such as FGF2, latent TGFb and connective tissue growth factor
(CTGF). In rested cartilage these molecules are held back from the cell
surface, but upon mechanical stimulation they are released causing
cellular activation (Vincent et al. 2007, and unpublished results). Data
presented at OARSI 2014 revealed that CTGF and latent TGFb are
released in a high molecular weight complex upon cartilage injury. In
this study we extend these results to address how CTGF controls the
release and activation of latent TGFb.
Methods: CTGF ﬂoxed mice were crossed with ubiquitin Cre-ERT2 mice
to generate post natal, pan-tissue, tamoxifen-inducible CTGF knockout
mice. Femoral head avulsion of wild type or knockout tissue into serum
freemediumwas used as an injurymodel.Medium conditioned for up to
24hourswas analysed for CTGFandTGFbprotein, andphosphoSMAD2/3
activity. Selected cell surface receptors were blocked to assess their
involvement in activation of latent TGFb in the cut conditionedmedium.
Results: Medium conditioned by avulsion injury of CTGF knockout
murine cartilage conﬁrmed reduced levels of CTGF protein. Surpris-
ingly, levels of TGFb in the injury CMwas similar betweenwild type and
knockout tissues suggesting that CTGF was not required for the release
of latent TGFb from the pericellular matrix. However, injury CM gen-
erated from CTGF knockout cartilage showed reduced SMAD2/3 activity
in isolated porcine chondrocytes compared with activity from injured
wild type cartilage, indicating that CTGF is involved in the activation of
latent TGFb at the cell surface. Incubation of porcine chondrocytes with
either an RGD- integrin binding peptide or a blocker of LRP1 (scavenger
receptor which is known to internalise CTGF) did not affect SMAD2/3
activity in the injury medium suggesting that these known binding
partners of CTGF are unlikely to be involved in the CTGF-dependent
activation of latent TGFb.
Conclusions: Our results show CTGF has a critical role in activating
latent TGFb at the cell surface and is not required for the release of
latent TGFb from the pericellular matrix of cartilage upon injury.
26
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